Managing non-Alzheimer's dementia with pharmacotherapy

Geriatrics and Aging

Volumn 11, Issue 9, 2008, Pages 515-521

  Alagiakrishnan, Kannayiram ^a   Sadowski, Cheryl A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cholinesterase inhibitors; Lewy body dementia; Mixed dementia; Parkinson disease dementia; Vascular dementia

Indexed keywords

EID: 55849092111     PISSN: 14888408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. World Health Organization, World Health Report 2003 - Shaping the Future. Geneva: The Organization; 2003.
2. Tohgi H, Abe T, Kimura M, et al. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer's type dementia. J Neural Transm 1996;103:1211-20.
3. Seiden NR, Gitelman DR, Salamon-Murayama N, et al. Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain 1998;121:2249-57.
4. Swartz RH, Black SE. How common is vascular compromise of cholinergic white matter pathways in a memory clinic sampie? J Neurol Sci 2002;203-4:281.
5. Ballard C, McKeith I, O'Brien J, et al. Neuropathological substrates of dementia and depression in vascular dementia, with particular focus on cases with small infarct volumes. Dementia 2000;11:59-65.
6. Tiraboschi PHL, Alford M, Sabbagh MN, et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000;54:407-11.
7. Ziabreva I, Ballard CG, Aarsland D, et al. Lewy body disease: thalamic cholinergic activity related to dementia and parkinsonism. Neurobiol Aging 2006;27:433-8.
8. Perry E, McKeith I, Ballard C. Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies. Neurology 2003;60:1852-3.
9. Wilkinson D, Doody R, Helme R, et al; Donepezil 308 Study Group. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003;4:479-86.
10. Black S, Roman GC, Geldmacher DS, et al. Donepezil 307 Vascular Dementia Study Group. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomised, placebo-controlled trial. Stroke 2003;34: 2323-30.
11. Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev 2004; 1:CD004395. DOI: 10.1002/14651858.CD004395.pub2.
12. Moretti R, Torre P, Antonello RM, et al. Rivastigmine in sub-cortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow up. Eur J Neurol 2001;8:361-2.
13. Moretti R, Torre P, Antonello RM, et al. Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients. Am J Alzheimers Dis Other Demen 2003;18:265-72.
14. Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial. Lancet 2002;359:1283-90.
15. Craig D, Birks J. Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev 2006;1:CD004746. DOI: 10.1002/14651858.CD004746.pub2.
16. Orgogozo JM, Rigaud AS, Stoffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002;33:1834-9.
17. Wilcock G, Mobius HJ, Stoffler A. MMM500 group. A double-blind placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002;17:297-305.
18. McKeith I, Del Ser, T, Spano PF, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet 2000;356:2031-6.
19. Edwards K, Royall D, Hershey L, et al. Efficacy and safety of galantamine in-patients with dementia with Lewy bodies: a 24-week open-label study. Dement Geriatr Cogn Disord 2007;23:401-5.
20. Thomas AJ, Burn DJ, Rowan EN, et al. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies. Int J Geriatr Psych 2005;20:938-44.
21. Wild R, Pettit T, Burns A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev 2003;3:CD003672. DOI: 10.1002/14651858.CD003672.
22. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-18.
23. Aarsland D, Litvan I, Salmon D, et al. Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003;74:1215-20.
24. Leroi I, Brandt J, Reich SG, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004;19:1-8.
25. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's diease: a randomized, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005;76:934-9.
26. Moretti R, Torre P, Antonello MR, et al. Rivastigmine in frontotemporal dementia, an open-label study. Drugs Aging 2004;21:931-7.
27. Lyketsos CG, Toone L, Tschanz JT, et al. Mental and behavioral disturbances in dementia; findings from the Cache County Study on memory in aging. Am J Psychol 2000;157:708-14.
28. Levy ML, Miller BL, Cummings JL, et al. Alzheimer's and frontotemporal dementias. Behavioral distinctions. Arch Neurol 1996;53:687-90.
29. Snowden J, Bathgate D, Varma A, et al. Distinct behavioral profiles in frontotemporal and semantic dementia. J Neurol Neurosurg Psych 2001;70:323-32.
30. Aarsland D, Ballard C, Larson JP, et al. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psych 2001;16:528-36.
31. Del-ser T, McKeith I, Anand R, et al. Dementia with Lewy bodies: findings from an international multicentre study. Int J Geriatr Psychiatry 2000;15:1034-45.